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Abstract
Interferon alpha (IFN-a) binds to a cell surface receptor that activates the Jak-Stat signaling pathway. A critical com-
ponent of this pathway is the translocation of interferon stimulated gene factor 3 (a complex of three proteins
Stat1, Stat2 and IRF9) to the nucleus to activate antiviral genes. A stable sub-genomic replicon cell line resistant to
IFN-a was developed in which the nuclear translocation of Stat1 and Stat2 proteins was prevented due to the lack
of phosphorylation; whereas the nuclear translocation of IRF9 protein was not affected. In this study, we sought to
overcome defective Jak-Stat signaling and to induce an antiviral state in the IFN-a resistant replicon cell line by
developing a chimera IRF9 protein fused with the trans activating domain (TAD) of either a Stat1 (IRF9-S1C) or
Stat2 (IRF9-S2C) protein. We show here that intracellular expression of fusion proteins using the plasmid constructs
of either IRF9-S1C or IRF9-S2C, in the IFN-a resistant cells, resulted in an increase in Interferon Stimulated Response
Element (ISRE) luciferase promoter activity and significantly induced HLA-1 surface expression. Moreover, we show
that transient transfection of IRF9-S1C or IRF9-S2C plasmid constructs into IFN-a resistant replicon cells containing
sub-genomic HCV1b and HCV2a viruses resulted in an inhibition of viral replication and viral protein expression
independent of IFN-a treatment. The results of this study indicate that the recombinant fusion proteins of IRF9-S1C,
IRF9-S2C alone, or in combination, have potent antiviral properties against the HCV in an IFN-a resistant cell line
with a defective Jak-Stat signaling.
Introduction
H e p a t i t i sCv i r u s( H C V )i n f e c t i o ni sam a j o rp u b l i c
health problem with 170 million infected individuals
worldwide [1,2]. HCV infection establishes a chronic
inflammatory liver disease in over 70 percent of patients.
In chronically infected individuals the disease slowly
progresses over decades resulting in liver cirrhosis,
hepatocellular carcinoma (HCC), and liver failure [3].
The World Health Organization estimates that 3% of
the world’s population is infected with HCV and
approximately three to four million new cases of HCV
infection occur globally per year [4]. Pegylated IFN-a
plus ribavirin is the standard of care for the treatment
of chronic HCV infection [5,6]. Approximately one half
of treated patients clear the virus infection with this
regimen and as many as 20% of patients prematurely
discontinue therapy due to side effects [7]. The molecu-
lar details that determine response to treatment are not
well understood.
IFN-a signal transduction is initiated by the binding of
the IFN-a molecule to its surface receptor. This binding
activates the receptor associated tyrosine kinases, Janus
kinase 1 (Jak-1) and tyrosine kinase 2 (Tyk2), which
then phosphorylate Stat1 and Stat2 proteins. Phosphory-
lated Stat1 and Stat2 then disassociate from the receptor
and form the hetero-trimeric IFN-stimulated gene factor
3 (ISGF3) complex which then translocates into the
nucleus and induces antiviral gene transcription. This
cascade of biochemical reactions occurring in normal
cells following IFN-a treatment is called the Jak-Stat
pathway [8]. * Correspondence: sdash@tulane.edu
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described to be related to several viral and host related
factors [9-11]. For this purpose, we have developed mul-
tiple IFN-a resistant cell lines containing sub-genomic
HCV RNA as a model to study IFN resistance. Charac-
terization of these cell lines have revealed that Jak-Stat
pathway defects give rise to the IFN-a resistant pheno-
type [12,13]. A more recent analysis revealed that each
of our nine resistant cell lines express a truncated IFN-a
receptor 1 (IFNAR1), resulting in the functional inacti-
vation of the IFN-a receptor (unpublished data). A
f u s i o np r o d u c to fI R F 9t ot h eT A Do fe i t h e rS t a t 1o r
Stat2 was previously engineered [14]. We show here
that intracellular expression of an IRF9-Stat fusion pro-
tein in an IFN-resistant replicon cell line bypasses cellu-
lar defects and induces transcription of the genes under
the control of the interferon sensitive response element
(ISRE) promoter. Furthermore, we show here that intra-
cellular expression of these constructs in an IFN-a resis-
tant cell line containing sub-genomic HCV RNA
inhibited viral replication and viral protein expression
and induced HLA-1 surface expression without IFN-a
treatment. These studies provide evidence that targeting
the Stat1 or Stat2 proteins can induce an intracellular
antiviral state independent of the IFN treatment thus
providing an alternative strategy to overcome HCV
resistance to standard IFN-a based therapy.
Materials and methods
IFN-a resistant HCV replicon cell lines
IFN-a resistant cells containing sub-genomic HCV geno-
type 1b RNA were generated in our laboratory by pro-
longed treatment of the low inducer replicon cell line
Con-15-3 with IFN-a as described previously [12]. IFN
sensitive S9-13 cells containing sub-genomic HCV geno-
type 1b HCV RNA were kindly provided by Ralf Bar-
tenschlager, University of Heidelberg, Heidelberg,
Germany. Stable cell lines, S3-GFP (IFN sensitive) and
R4-GFP (IFN resistant) containing HCV genotype 2a
subgenomic RNA with a green fluorescence protein
(GFP) fusion in frame with HCV NS5A were prepared
in our laboratory as previously described [13]. All cell
lines were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 2 mM L-gluta-
mine, nonessential amino acids, 100 U/ml of penicillin,
100 μg/ml of streptomycin, 500 μg/ml of G418, and 5%
fetal bovine serum.
Plasmid constructs and DNA transfection
Three different expression plasmid constructs (Fig. 1)
were used in this study and assessed for their ability to
overcome defective Jak-Stat signaling and to induce an
antiviral state in R15-3 cells. The first plasmid,
pcDNA3-IRF9 contains the open reading frame of the
human IRF9 gene under the control of a cytomegalo-
virus (CMV) promoter. The second plasmid, IRF9-S1C
contains the 38 C-terminal amino acids of Stat1 pro-
tein fused in frame with the human IRF9. The third
plasmid construct, IRF9-S2C contains the 104 C-term-
inal amino acids of Stat2 fused in frame with the
human IRF9 coding sequence. All three recombinant
plasmid constructs were obtained as a gift from Curt
Horvath, Feinberg School of Medicine, Northwestern
University, Evanston, Illinois [14]. The ISRE-Luciferase
plasmid was obtained from Steve Goodbourn, St.
George’s Hospital, University of London, London, UK
[15]. The pRL-TK plasmid was obtained from Promega
Corporation, Madison, WI. The Stat1-GFP and IRF9-
GFP constructs were obtained from Addgene Inc,
Cambridge, MA [16]. The Stat2-GFP construct was
obtained from Dr. Mario Koster Braunschweig, Ger-
many [17]. DNA transfections were performed using
Fugene-6 transfection reagent following the manufac-
turer’s recommendations (Roche Molecular Diagnos-
tics, Indianapolis, IN).
Luciferase Reporter Assays
The R15-3 cell line was transfected using either IRF9,
IRF9-S1C, or IRF9-S1C plus IRF9-S2C plasmid, ISRE
firefly-luciferase (FL) plasmid, pRL-TK renilla-luciferase
(RL) plasmid and treated with or without IFN-a (Scher-
ing, Kenilworth, NJ). At 24 hours post-transfection FL
and RL activity was measured by integrating the total
light emission over ten seconds with a luminometer
(Luman LB9507, EG&G Bethold, Berlin, Germany). The
results were normalized by dividing the FL value with
the RL value for the same sample.
Nuclear Translocation Assay
R15-3 and 9-13 cells were were plated in a two well
Lab-Tek chamber slide (Electron Microcopy Sciences,
Hatfield, PA) at a density of 5 × 10
4 cells per ml.
Twenty four hours later, cells were transfected with 1
μg of the respective Stat1-GFP, Stat2-GFP or IRF9-GFP
plasmid DNA using Fugene-6 transfection reagent. At
48 hours post- transfection, To-Pro3 nuclear marker
(Invitrogen, Molecular Probes, Oregon) was added to
the samples at 1 μg/ml, and incubated for five minutes
in PBS. IFN-a (1000 IU/ml) was then added to the
appropriate groups. Confocal microscopy was performed
using a Leica TCS SP2 confocal microscope equipped
with three lasers (Leica Microsystems, Exton, PA). Opti-
cal slices were collected at 512 × 512 pixel resolution.
NIH Image version 1.62 and Adobe Photoshop version
7.0 were used to assign correct colors of channels col-
lected, including the Green Fluorescent Protein (green),
To-Pro3 633 (far red), and the differential interference
contrast image (DIC) (gray scale).
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R15-3 and 9-13 cells were transfected with IRF9, IRF9-
S1C, IRF9-S2C, or IRF9-S1C plus IRF9-S2C plasmid. At
48 hours post-transfection the cultured cells were sus-
pended in 100 μlo fP B Sa n d2 0μl of phycoerythrin
conjugated mouse anti-human HLA-ABC antibody
(Pharmingen, San Jose, CA) and incubated for 15 min-
utes at 4°C. The cells were then resuspended in 500 μl
of PBS and analyzed by a BD LSR-II flow cytometer
(Becton-Dickinson, Franklin Lakes, New Jersey) using
BD FACS Diva software.
Ribonuclease Protection Assay (RPA) of the HCV Negative
Sense Strand RNA
The antiviral properties of each IRF9 construct was eval-
uated by RPA detection of the HCV RNA negative sense
strand utilizing a previously described method [15]. R15-
3 cells were transfected with IRF9, IRF9-S1C, IRF9-S2C,
or IRF9-S1C plus IRF9-S2C plasmid in the presence or
absence of IFN-a (1,000 IU/ml). At 72 hours total RNA
was isolated, hybridized, and analyzed by RPA.
Real-time RT-PCR
R15-3 cells were transfected with IRF9, IRF9-S1C, IRF9-
S2C, or both IRF9-S1C, and IRF9-S2C plasmid. At 72
hours real time RT-PCR was used to quantify HCV
RNA levels using a previously described method [13].
S9-13 and R15-3 cells with and without IFN-a (1,000
IU/ml) treatment were used as positive and negative
controls respectively. Values represent the mean log
copies of HCV RNA per μg of cellular RNA from three
experiments. Error bars represent standard deviation
(SD). The student’s t-test was used to compare R15-3
transfected cells to R15-3 cells plus IFN-a (1,000 IU/ml).
Values < 0.05 were considered significant.
Immunocytochemical staining
R15-3 cells were transfected with IRF9, IRF9-S1C, IRF9-
S2C or both IRF9-S1C, and IRF9-S2C, and were treated
with or without IFN-a (1,000 IU/ml). At 48 hours the
cells were mounted onto a glass slide and stained for
HCV NS3 utilizing a previously described method [12].
Analysis of Stat1 Phosphorylation by Co-
immunoprecipitation
R15-3 and S9-13 cells were transfected with each of the
plasmids listed in Fig. 1A. At 72 hours the cells were
treated with or without IFN-a (1000 IU/ml). Forty-five
minutes after IFN-a addition the cells were lysed by the
Figure 1 Structure of plasmid constructs. (A) The plasmid constructs containing the full-length clones of IRF9, Stat1 and Stat2 fused with GFP
either at the N-terminal or C-terminal ends. (B) Full length IRF9 clone fused with the TAD of either Stat1 or Stat2. IRF9-S1C contains the full
length IRF9 molecule fused in frame with the 38 C-terminal amino acids of Stat1. IRF9-S2C also contains the full length IRF9 molecule fused in
frame with the 104 C-terminal amino acids of Stat2. (C) The ISRE reporter plasmid containing four copies of ISRE sequences positioned upstream
of the HSV thymidine kinase (TK) promoter TATA box that drives the expression of FL. The bottom construct, used as a transfection control
contains RL downstream of a HSV TK promoter.
Poat et al. Virology Journal 2010, 7:265
http://www.virologyj.com/content/7/1/265
Page 3 of 12addition of RIPA buffer with proteinase and phosphatase
inhibitors (1 × PBS, 1% NP-40, 0.5% Deoxycholate, 0.1%
SDS, 50 μg/ml PMSF, 5 μg/ml aprotinin, 5 μg/ml leu-
peptin, 1 μg/ml pepstatin). The GFP primary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) was added
to the lysate and rotated at 4°C overnight. The next
morning protein A/G plus-agarose (Santa Cruz Biotech-
nology, Santa Cruz, CA) was added to each sample and
rotated at 4°C for three hours. Western blotting was
then performed using a Phospho-Stat1 Y701 (p-Stat1)
primary antibody (Cell Signaling Technology, Danvers,
MA) diluted (1:1,000) in blocking reagent, (0.1% tween
20, Tris buffered saline, and 5% NFDM) as described
below.
Immunoblot Blot Analysis
Cell lysates were prepared from IRF9, IRF9-S1C, IRF9-
S2C, or both IRF9-S1C, and IRF9-S2C transfected R15-3
cells at 72 hours post-transfection. Western blot analysis
was then performed using HCV NS5B (Abcam, Cam-
bridge, MA), p-eIF-2a (Cell Signalling Technologies,
Danvers, MA) and b-actin (Cell Signalling Technologies,
Danvers, MA) primary antibodies.
MTT Assay
The viability of IRF9 fusion construct transfected R15-3
cells was evaluated by the MTT assay. At 72 hours
post-transfection 100 μl of the MTT solution (Sigma, St.
Louis, MO) was added to the media in each well. After
three hours of incubation at 37°C the media was aspi-
rated and 1 ml of solubilization buffer (0.1 N HCL in
absolute isopropanol) was added to each well. The
absorbance of each sample was then measured at 570
nm utilizing a Beckman DU Spectrophotometer after
blanking. The viability was then calculated by the for-
mula dividing the OD570 of each sample by the mean
OD570 of the controls.
Results
IFN-a independent nuclear localization of IRF9 in the R15-
3 and S9-13 cells
The GFP fused Stat1, Stat2 and IRF9 plasmid clones
illustrated in Fig. 1A were used to establish the
dynamics of nuclear translocation in the S9-13 and R15-
3 cells in the presence and absence of IFN-a. Using a
transient transfection experiment, we demonstrate that
both the Stat1-GFP and Stat2-GFP fusion proteins were
expressed at high levels in the cytoplasm of both cell
lines. Both the Stat1-GFP and Stat2-GFP fusion protein
translocated to the nucleus of S9-13 cells 30 minutes
after IFN-a treatment and returned to the cytoplasm by
24 hours (Fig. 2). However, the Stat1-GFP and Stat2-
GFP proteins did not localize to the nucleus of the R15-
3 cell line following IFN-a treatment. These results
suggest that the nuclear trans l o c a t i o no ft h eS t a t 1a n d
Stat2 proteins were impaired in the R15-3 cells. The
IRF9-GFP fusion protein was expressed at intermediate
levels in the S9-13 and R15-3 cell lines. The distribution
of IRF9-GFP chimera protein was localized in both the
cytoplasm and nucleus at all time points in both the
R15-3 and S9-13 cell lines. These results suggest that
the IRF9 protein diffuses freely from cytoplasm to the
nucleus of both cell lines independent of IFN-a treat-
ment. To understand the reason for differences in the
nuclear translocation of Stat1 and Stat2-GFP fusion pro-
teins in R15-3 and S9-13 cells, their phosphorylation
status was examined after transfection. The co-immuno-
precipitation experiments show that the Stat1-GFP and
Stat2-GFP proteins were phosphorylated in the S9-13
cells but not in the R15-3 cells (Fig. 3).
Intracellular expression of IRF9-Stat fusion protein
activates ISRE transcription
Since the IRF9-GFP construct efficiently localized to the
nucleus of the R15-3 cells, we wanted to test whether
fusing the TAD of either the Stat1 or Stat2 protein
could induce IFN promoter activation. For this reason,
expression plasmid constructs of IRF9 fused with the
TAD of either Stat1 or Stat2 (Fig. 1B) were tested for
their ability to activate the ISRE promoter in the R15-3
cell line. Intracellular expression of IRF9 after plasmid
DNA transfection did not activate the ISRE-luciferase
activity in the R15-3 cell line even after IFN-a treatment
(Fig. 4), whereas the IRF9-S1C and IRF9-S2C fusion
constructs significantly induced the ISRE-luciferase pro-
moter (p < .025). The combination treatment with both
IRF9-S1C and IRF9-S2C also showed high ISRE-lucifer-
ase activity in the R15-3 cells. There were no significant
differences (p < .05 student’s t-test) in ISRE-luciferase
activity between the IFN-a (+) and (-) groups suggesting
that the ISRE-luciferase induction was IFN independent.
These results suggest that the fusion of the TAD of
either Stat1 or Stat2 to IRF9 efficiently localized to the
nucleus and activated the ISRE promoter in the R15-3
cell line. The results of the ISRE promoter induction
experiments were confirmed by examining the HLA-
ABC (HLA-1) surface expression of IRF9-Stat fusion
transfected R15-3 cells by flow cytometry at 72 hours
post-transfection. HLA-1 is an important molecule
induced by the ISRE promoter which is involved in the
immune recognition of virally infected cells [8]. Intracel-
lular expression of either IRF9-S1C or IRF9-S2C
induced HLA-1 surface expression in the R15-3 cells
(Fig. 5A). The change in surface HLA-1 expression in
R15-3 cells following plasmid transfection was quanti-
fied and compared to the fold change in HLA-1 surface
expression of untransfected R15-3 cells after the addi-
tion of IFN-a (Fig. 5B). Significant increases (p < .05) in
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S2C and IRF9-S1C plus IRF9-S2C transfected R15-3
cells. In the control S9-13 cells, the expression of HLA-
1 was induced after IFN-a treatment.
Efficient clearance of HCV replication from R15-3 cell line
expressing IRF9-Stat fusion proteins
The ability of the different IRF9-Stat fusion plasmids to
inhibit viral replication was examined using stable repli-
con cell lines containing either HCV genotype 1b or
HCV 2a sub-genomic RNA. RPA detection of the HCV
negative strand RNA replication intermediate was used
to assess viral replication in IRF9-Stat fusion transfected
R15-3 cells. The RPA results demonstrate that intracel-
lular expression of IRF9 alone had no effect upon HCV
negative strand RNA levels, whereas all of the IRF9-Stat
fusion constructs showed antiviral activity in an IFN-a
independent manner (Fig. 6A). Transfection with IRF9-
S1C reduced HCV negative sense RNA strand levels,
and IRF9-S2C alone or in combination with IRF9-S1C
inhibited HCV replication below the limit of detection
of the RPA assay. The HCV negative strand RNA RPA
Figure 2 Nuclear translocation of STAT-GFP constructs. The S9-13 and R15-3 cell lines were transfected with IRF9, Stat1, or Stat2 GFP fusion
constructs (-) and (+) IFN-a (1,000 IU/ml) and their nuclear translocation was observed under a confocal microscope. The images are represented
as the superimposition of Green Fluorescent Protein (green), To-Pro3 633 (far red), and the differential interference contrast images (DIC) (gray
scale). Fluorescence green and red microscopic picture of the same area were taken and superimposed using Abode Photoshop. Left panel
shows high resolution picture showing that the IRF9-GFP fusion protein translocates to the nucleus of both S9-13 and R15-3 cells in an IFN-a
independent manner. Middle panel shows stat1-GFP fusion protein efficiently localized to the nucleus of S9-13 cells within 30 minutes after
IFN-a treatment. Stat1-GFP was unable to localize to the nucleus in R15-3 cells. Right panel shows stat2-GFP efficiently localized to the nucleus
of S9-13 cells within 30 minutes after IFN-a treatment. Stat2-GFP was unable to localize to the nucleus in R15-3 cells.
Figure 3 Phosphorylation of Stat1-GFP and Stat2-GFP fusion proteins in S9-13 and R15-3 cells determined by co-immunoprecipitation.
S9-13 and R15-3 cells were transfected with either Stat1-GFP or Stat2-GFP. After 48 hours IFN-a (1,000 IU/ml) was added. Protein lysates were
prepared, subjected to immunoprecipitation with a GFP antibody, and western blot analysis was performed using a p-STAT1 antibody.
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RNA by real-time RT-PCR. The results in Fig. 6B
demonstrate that R15-3 cells transfected with IRF9-S1C,
IRF9-S2C, or the combination experienced a significant
reduction (p < .05) in log copies of HCV RNA per μgo f
cellular RNA compared to R15-3 cells plus IFN-a (1,000
IU/ml). IRF9 alone transfected R15-3 cells and showed a
modest reduction of HCV RNA. S9-13 cells with and
without IFN-a (1,000 IU/ml) were used as a positive
control.
Viral protein expression was assessed by immunocyto-
chemical staining for HCV NS3 protein. The results pre-
sented in Fig. 7A suggest that the transfection of R15-3
cells using the individual constructs IRF9-S1C, IRF9-
S2C or the combination reduced HCV NS3 protein
expression in an IFN-a independent manner. The IRF9
alone-transfected R15-3 cells showed no reduction in
viral protein levels while the IRF9-S1C, IRF9-S2C and
the combination of both transfected R15-3 cells dis-
played a reduction of HCV NS3 expression (Fig. 7A).
The addition of IFN-a had no effect on viral protein
levels in each experimental group. Western blot analysis
was then performed using an antibody against HCV
NS5B to verify the results of the antiviral effect of the
IRF9-Stat fusions. IRF9-S2C and IRF9-S1C plus IRF9-
S2C reduced HCV NS5B protein levels in R15-3 cells
(Fig. 7B). R15-3 cells transfected with IRF9 alone
showed no reduction in HCV NS5B, while the IRF9-S1C
transfected cells showed weak reduction in viral protein
expression. All constructs exerted their antiviral activity
in an IFN independent manner. The antiviral properties
of the IRF9-Stat fusion constructs appear more robust
at the 72 hour time point as compared to the previous
immunocytochemical assessment of HCV NS3 at 48
hours. This increase in antiviral efficacy between these
time points correlates with our experience with the anti-
viral activity of IFN-a in the S9-13 cell line. The antiviral
effect of IRF9-Stat fusion protein expression in the HCV
2a-GFP resistant replicon cells (R4-GFP) was examined
directly via fluorescence microscopy and then quantified
by flow analysis (Fig. 8). It was determined that R4-GFP
cells expressing IRF9 alone had no antiviral effects
whereas all the remaining constructs had potential anti-
H C Va c t i v i t ya st h e ya l li n h i b i t e dH C V - G F Pe x p r e s s i o n
to various degrees. The strongest antiviral activity was
observed in the IRF9-S2C transfected cells. The viability
of the R15-3 cell line expressing different IRF9-Stat
fusion constructs was then examined to exclude the
possibility that the enhanced viral clearance was not due
to the toxic effect of intracellular expression of the
IRF9-Stat fusion proteins. The results presented in Fig.
9 suggest that no cellular toxicity was associated with
the expression of the Stat fusion proteins in the R15-3
cells. Taken together, these results suggest that the
intracellular expression of IRF9-S1C and IRF9-S2C leads
to effective clearance of HCV RNA replication in an
IFN-a resistant replicon cell line of both HCV1b and
HCV2a genotype viruses.
Next, the mechanism of inhibition of viral RNA repli-
cation in cells expressing the IRF9-Stat fusions was
Figure 4 Analysis of ISRE-luciferase promoter activation due to intracellular expression of IRF9-Stat fusion proteins. R15-3 cells were
transfected with IRF9, IRF9-S1C or IRF9-S2C plasmid and cultured (-) and (+) IFN-a (1,000 IU/ml). At 48 hours FL and RL activity were measured.
Values are expressed in RL normalized units and error bars represent the SEM from three experiments. The Student’s t-test was used to compare
IRF9 with and without IFN to IRF9-S1C, IRF9-S2C and IRF9-S1C plus IRF9-S2C with and without IFN. Values <.05 were considered significant.
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the antiviral state and which is activated upon ISRE pro-
moter induction is the phosphorylation of eIF2a. Phos-
phorylation of eIF2a leads to translational inhibition
within the cell thereby preventing viral replication.
Therefore, we assessed the ability of each construct to
induce p-eIF2a both in the presence and absence of
IFN-a. The result shown in Fig. 10 suggests that IRF9
alone was unable to induce p-eIF2a, while IRF9-S1C
caused low-level induction of p-eIF2a. Transfection of
IRF9-S2C alone and IRF9-S1C plus IRF9-S2C caused
high-level p-eIF2a induction. The addition of IFN-a did
not significantly (p < .025) alter the expression patterns
of p-eIF2a.
Discussion
The molecular mechanisms of IFN-a resistance are
unclear, however a number of studies have provided evi-
dence that both viral and cellular factors are involved
[18-23]. We provided evidence that replicon cells
develop IFN-a resistance due to defective Jak-Stat sig-
naling. Using long-term IFN-a treatment of replicon
cells we have established IFN-a resistant sub-genomic
HCV based stable replicon cell lines for HCV 1b and
HCV 2a genotype viruses. Replication of HCV RNA in
these stable cell lines remained resistant to IFN-a due to
defects in Stat1 and Stat2 phosphorylation and the sub-
sequent impairment of nuclear translocation of ISGF3.
In this study, a potential therapeutic strategy against
chronic HCV infection using a chimeric protein of IRF9
fused to the TAD of either the Stat1 or Stat2 molecule
of the Jak-Stat signaling pathway was examined.
We showed that the IRF9 protein was expressed at
intermediate levels in the R15-3 cells after transfection
and efficiently localized to the nucleus, suggesting that
the nuclear translocation of IRF9 protein in the R15-3
cells is not dependent upon IFN-a induced Jak-Stat sig-
naling. Nuclear translocation of the Stat1-GFP and
Figure 5 Intracellular expression of IRF9-S1 or IRF9-S2C induced HLA-1 surface expression in the R15-3 cells. S9-13 and R15-3 cells were
transfected and cultured (-) and (+) IFN-a (1,000 IU/ml). After 48 hours, HLA-1 surface expression was quantified by flow cytometry. (A) Shows
the HLA-1 surface expression in the IRF9-Stat fusion transfected R15-3 cells. The red cell population represents IFN-a naïve cells or untransfected
cells and the blue cell population represents IFN-a treated or transfected cells. IRF9-S1C, IRF9-S2C, and IRF9-S1C plus IRF9-S2C transfected R15-3
cells demonstrated significant increases in HLA-1 surface expression. (B) Each value represents the mean fluorescence intensity from six
experiments. The student’s t-test was used to compare the fold increase of transfected R15-3 cells to untransfected R15-3 cells plus IFN-a.
Asterisk (*) indicates transfected R15-3 cells with significantly different HLA-1 surface expression relative to untransfected R15-3 cells. Significance
was considered at p-values < 0.05.
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cell line; however the nuclear localization of Stat1-GFP
and Stat2-GFP did not occur in the R15-3 cells that pos-
sess defective Jak-Stat signaling. These results led us to
examine whether the development of a chimera protein
between the IRF9 and the TAD of either Stat1 or Stat2
protein could facilitate nuclear translocation and induce
IFN antiviral gene expression. We showed here that
intracellular expression of the IRF9-Stat1 and Stat2
fusion proteins in the R15-3 cell line activated the ISRE-
luciferase promoter in a concentration dependent man-
ner. Expression of the IRF9 protein alone did not acti-
vate the ISRE-luciferase promoter activity suggesting
that IRF9 alone does not control the antiviral gene tran-
scription induced by IFN-a. The results of this study
also validate the previous finding that the fusion of the
TAD of either Stat1 or Stat2 to IRF9 protein induced
the ISRE promoter [14]. The activity of IRF9-S2C was
stronger than IRF9-S1C. The recombinant IRF9-Stat
fusion constructs also induced HLA-1 surface expres-
sion in R15-3 cells in an IFN-a independent manner.
Based on these results we speculate that intracellular
expression of IRF9-S2C or IRF9-S1C in HCV infected
hepatocytes may induce HLA-1 surface expression and
may thus increase cytotoxic T lymphocyte (CTL)
mediated viral clearance. Interestingly we observed that
the intracellular expression of IRF9-S2C alone or the
combination with IRF9-S1C showed stronger activation
of ISRE-luciferase promoter activation than IRF9-S1C
alone, indicating that Stat2 expression contributes more
towards the potent antiviral activity against HCV
infected hepatocytes with defective Jak-Stat signaling.
On the other hand, intracellular expression of either
IRF9-S1C, IRF9-S2C or the combination of both show
similar results in the mobilization of HLA-1 surface
expression in R15-3 cells. These results suggest that
intracellular expression Stat1 fusion could contribute
Figure 6 Ribonuclease protection assay and Real-time RT-PCR of sub-genomic HCV 1b RNA. (A) Intracellular expression of IRF9-S1C and
IRF9-S2C or both in R15-3 cells inhibits HCV negative strand RNA detection by RPA. R15-3 cells were transfected treated (-) and (+) IFN-a (1,000
IU/ml), and total RNA was isolated at 72 hours post-transfection. The upper panel shows the RPA results of HCV negative strand detection. The
bottom panel shows GAPDH mRNA levels by RPA. (B) Real-time RT-PCR was performed to quantify HCV RNA in R15-3 transfected cells. Cellular
RNA was isolated at 72 hours, retrotranscribed, and assayed by real time PCR. S9-13 and R15-3 cells (+) and (-) IFN-a were used as (+) and (-)
controls, respectively. Error bars represent SD. Asterisk (*) indicates transfected R15-3 cells with significantly lower HCV RNA relative to
untransfected R15-3 cells treated with IFN. Significance was considered at p-values < 0.05.
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infected hepatocytes with defective Jak-Stat signaling.
The antiviral properties of the IRF9-Stat fusion pro-
teins were also examined using stable IFN-resistant cell
lines of HCV 1b and 2a genotype viruses. Using the
R15-3 cell line containing sub-genomic HCV genotype
1b RNA, we showed that intracellular expression of
IRF9-S1C and IRF9-S2C efficiently inhibited negative
strand HCV RNA levels and viral NS3 protein expres-
sion in a replicon cell line containing defective Jak-Stat
signaling. This approach was also tested using IFN-a
resistant HCV 2a sub-genomic GFP replicon. We
showed that transient transfection of IRF9-S1C and
IRF9-S2C or both inhibited GFP expression in an IFN-a
independent manner. These results suggest that this
antiviral strategy may be effective against different HCV
Figure 7 Immunostaining of HCV NS3 and Western blot of HCV NS5B proteins. (A) The antiviral activity of the IRF9-Stat fusion constructs
in R15-3 cells containing HCV 1b sub-genomic RNA HCV. At 48 hours post-transfection the cells were mounted onto a glass slide, stained for
HCV NS3 protein and counterstained with hematoxylin. Panel i and ii: Huh-7 cells (-) and (+) IFN-a (1,000 IU/ml). Panel iii and iv: R15-3 cells (-)
and (+) IFN-a. Panel v: IRF9 transfected R15-3 cells Panel vi: IRF9-S1C transfected R15-3 cells Panel vii: IRF9-S2C transfected R15-3 cells Panel viii:
IRF9-S1C plus IRF9-S2C transfected R15-3 cells. (B) Upper panel: HCV NS5B expression levels in R15-3 transfected cells at 72 hours post-
transfection. Lower panel: Shows b-actin protein expression levels using equal amounts of protein lysate.
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of HCV replication in the R15-3 cell line, the protein
kinase R (PKR) mediated eIF-2a phosphorylation path-
way was examined by western blot analysis. Our results
suggest that the mechanism of inhibition of viral replica-
tion by intracellular IRF9-Stat fusion expression is
similar to that described for IFN-a and involves PKR
induced eIF-2a phosphorylation [24].
A critical determinant in the outcome of HCV infec-
tion is the host’s ability to mount an effective HCV spe-
cific CD8+ T cell response. It was also previously
demonstrated that a defective Jak-Stat system
Figure 8 The antiviral activity of the IRF9-Stat fusion constructs in an IFN resistant cell line containing HCV 2a sub-genomic RNA (R4-
GFP). (A) GFP expression levels in R4-GFP cells transfected with IRF9, IRF9-S1C and IRF9-S2C at 72 hrs post-transfection. (B) Flow cytometric
analysis of mean fluorescence intensity of R4-GFP transfected cells at 72 hrs. S3-GFP and R4-GFP cells treated with and without IFN-a were used
as controls. The error bars represent the SEM from three experiments. The Student’s t-test was used to compare R4-GFP transfected cells to R4-
GFP cells plus IFN-a. P-values < 0.05 were considered significant.
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It is therefore conceivable that the ineffective CD8+
responses of chronically infected HCV patients and IFN
non-responders may in part be linked to the inability of
infected hepatocytes to surface display the HLA-1: anti-
gen complex. This impaired surface presentation may
also contribute to the immune evasion observed in
virally infected hepatocellular carcinoma cells. A sub-
stantial body of clinical evidence exists to support the
role of dysregulated Jak-Stat signaling in IFN non-
response in chronic HCV infection [26-29]. These clini-
cal studies as well as our cell culture studies support the
importance of Jak-Stat signaling in infected hepatocytes
in viral persistence and response to IFN-a treatment.
Using HCV cell culture models we now provide
evidence that components of the Jak-Stat pathway can
be engineered to circumvent defective signaling thereby
inducing an antiviral state resulting in HCV eradication
without IFN-a treatment. Based on these in vitro studies
we propose that combination treatment using IRF9-S1C
and IRF9-S2C recombinant proteins may provide a
rationale for future development of an antiviral strategy
to overcome IFN-a resistance by circumventing Jak-Stat
cellular defects in chronically infected liver cells. We
propose that liver targeted delivery of IRF9-Stat fusion
protein can be used as a second line treatment in
chronically infected hepatitis C patients with defective
Jak-STAT signaling in an attempt to stimulate an anti-
viral response as well as increase HLA-1 expression in
hepatocytes in an IFN-a independent manner.
Figure 9 MTT Assay of IRF9-Stat fusion constructs in resistant cell line. R15-3 cells were transfected with IRF9 constructs and at 72 hours
post-transfection cell viability was determined by the MTT assay. Each value represents experiments performed in triplicate. Error bars represent
SEM.
Figure 10 Intracellular expression of IRF9-Stat fusion constructs induced eIF2a phosphorylation in the R15-3 cell line at 72 hours
post-transfection. Upper panel: Western blot of p-eIF2a in R15-3 cells transfected with different IRF9 plasmids in the absence and presence of
IFN-a (1,000 IU/ml). Bottom Panel: b-actin protein expression levels.
Poat et al. Virology Journal 2010, 7:265
http://www.virologyj.com/content/7/1/265
Page 11 of 12Acknowledgements
This work was supported by funds received from the National Cancer
Institute (CA127481, CA129776), Louisiana Board of Regents, Louisiana
Cancer Research Consortium and Tulane Cancer Center. The authors
acknowledge Dr. Curt Horvath, Feinberg School of Medicine, Northwestern
University, Illinois, USA for the generous gift of the IRF9-STAT recombinant
plasmids. The authors also acknowledge Dr. Mario Koster, Department of
Gene Regulation and Differentiation, GBF-National Research Institute for
Biotechnology, Braunschweig, Germany for kindly providing the STAT2-GFP
construct. Ralf Bartenschlager, University of Heidelberg, Heidelberg, Germany
for providing 9-13 cell line. The authors thank Dr. Astrid Engel, Dr. Sruti
Chandra, and Mallory Heath for critically evaluating this manuscript.
Author details
1Department of Pathology and Laboratory Medicine, Tulane University
Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA-70112, USA.
2Section of Gastroenterology and Hepatology, Tulane University Health
Sciences Center, 1430 Tulane Avenue, New Orleans, LA-70112, USA.
3Department of Microbiology and Immunology, Tulane University Health
Sciences Center, 1430 Tulane Avenue, New Orleans, LA-70112, USA.
4Division
of Comparative Pathology, Tulane National Primate Research Center, 18703
Three Rivers Road, Covington, LA-70433, USA.
Authors’ contributions
BP performed major biochemical experiments, participated in the design of
the study and wrote the initial draft of the manuscript. SH, PKC, FG and XA
did some biochemical experiments and participated in the design of the
study. SD and RFG supervised, helped to design the study and finally wrote
the manuscript. LAB share ideas and helped for manuscript preparation. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 17 July 2010 Accepted: 12 October 2010
Published: 12 October 2010
References
1. Alter MJ: Epidemiology of hepatitis C virus infection. World J Gastroenterol
2007, 13:2436-2441.
2. Sy T, Jamal M: Epidemiology of Hepatitis C virus infection. Int J Med Sci
2006, 3:41-46.
3. Post J, Ratnarajah S, Lloyd AR: Immunological determinants of the
outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009,
66:733-756.
4. Te HS, Jensen DM: Epidemiology of hepatitis B and C viruses: a global
overview. Clin Liver Dis 2010, 14:1-21.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr,
Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J,
Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus
infection. N Engl J Med 2002, 347:975-982.
6. Manns MP, McHutchison JG, Gordon SC: Peg-interferon alfa-2a plus
ribavirin compared with interferon alfa-2b plus ribavirin for initial
treatment of chronic hepatitis C: a randomised trial. Lancet 2001,
358:958-965.
7. Manns M, Wedemeyer H, Cornberg M: Treating viral hepatitis C: efficacy,
side effects, and complications. Gut 2006, 55:1350-1359.
8. Samuel CE: Antiviral actions of interferons. Clin Microbiol Rev 2001,
14:778-809.
9. Trepo C: Genotype and viral load as prognostic indicators in the
treatment of hepatitis C. J Viral Hepatitis 2000, 7:250-257.
10. Taylor DR, Shi ST, Lai MM: Hepatitis C virus and interferon resistance.
Microbes Infect 2000, 2:1743-1756.
11. He Y, Katze MG: To interfere and to anti-interfere: the interplay between
hepatitis C virus and interferon. Viral Immunol 2002, 15:95-119.
12. Hazari S, Taylor L, Garry RF, Dash S: Reduced expression of Jak-1 and Tyk-
2 proteins leads to interferon resistance in hepatitis C virus replicon.
Virol J 2007, 4:89.
13. Hazari S, Chandra PK, Poat B, Datta S, Garry RF, Dash S: Impaired antiviral
activity of IFN-α in Huh-7 cells with defective Jak-Stat pathway. Virol J
2010, 7:36.
14. Kraus TA, Lau JP, Parisien JP, Horvath CM: A hybrid IRF9-Stat2 protein
recapitulates interferon stimulated gene expression and antiviral
response. J Biol Chem 2003, 278:13033-13038.
15. Mirabel RS, Pai M, Prabhu R, Panebra A, Nangle S, Bastian F, Garry RF,
Agrawal K, Goodbourn S, Dash S: Activation of Interferon Stimulated
Response Element in a Huh-7 cell line replicating hepatitis C virus sub-
genomic RNA. Intervirology 2005, 48:301-311.
16. Timofeeva OA, Plisov S, Evseev AA, Peng S, Jose-Kampfner M, Lovvorn HN,
Dome JS, Perantoni AO: Serine-phosphorylated STAT1 is a prosurvival
factor in Wilms’ tumor pathogenesis. Oncogene 2006, 25:7555-7564.
17. Köster M, Hauser H: Dynamic redistribution of STAT1 protein in IFN
signaling visualized by GFP fusion proteins. Eur J Biochem 1999,
260:137-144.
18. Zhu H, Nelson DR, Crawford JM, Liu C: Defective Jak-Stat activation in
hepatoma cells is associated with hepatitis C viral IFN-α resistance. J
Interferon Cytokine Res 2005, 25:528-539.
19. Pawlotsky JM: The nature of IFN-α resistance in hepatitis C virus
infection. Curr Opin Infect Dis 2003, 16:587-592.
20. Pawlotsky JM: Mechanisms of antiviral treatment efficacy and failure in
chronic hepatitis C. Antiviral Res 2003, 59:1-11.
21. Gale MJ Jr, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ,
Gretch DR, Katze MG: Evidence that hepatitis C virus resistance to
interferon is mediated through repression of the PKR protein kinase by
the nonstructural 5A protein. Virology 1997, 230:217-227.
22. Gao B, Hong F, Radaeva S: Host factors and failure of IFN-α treatment in
HCV. Hepatology 2004, 39:880-890.
23. Su X, Yee LJ, Im K, Rhodes SL, Tang Y, Tong X, Howell C, Ramcharran D,
Rosen HR, Taylor MW, Liang TJ, Yang H, Virahep-C Study Group:
Association of single nucleotide polymorphisms in interferon signaling
pathway genes and interferon-stimulated genes with the response to
interferon therapy for chronic hepatitis C. J Hepatol 2008, 49:184-191.
24. Rivas-Estillas AM, Svitkin Y, Lastra ML, Hatzoglou M, Sherker A, Koromilas AE:
PKR-dependent mechanisms of gene expression from a subgenomic
hepatitis C virus clone. J Virol 2002, 76:10637-10653.
25. Rhodes SL, Erlich H, Im KA, Wang J, Li J, Bugawan T, Jeffers L, Tong X, Su X,
Rosen HR, Yee LJ, Liang TJ, Yang H, Virahep-C study group: Association
between the human MHC and sustained virologic response in the
treatment of chronic hepatitis C virus infection. Genes Immun 2008,
9:328-333.
26. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM,
Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Corrington M:
Variants in IFN-α pathway genes and response to pegylated IFN-α2a
plus ribavirin for treatment of chronic hepatitis C virus infection in the
hepatitis C Antiviral Long-term treatment against Cirrhosis trial.
Hepatology 2009, 49:1847-1858.
27. Aceti A, Zechini B, Griggi T, Marangi M, Pasquazzi C, Quaranta G, Sorice M:
Undetectable phospho-STAT1 in peripheral blood mononuclear cells
from patients with chronic hepatitis C who do not respond to IFN-α
therapy. Liver Int 2005, 5:987-993.
28. Miyaaki H, Ichikawa T, Nakao K, Takeshita S, Shibata H, Ozawa E, Akiyama M,
Miuma S, Eguchi K: Predictive value of the phosphorylation of signal
transducers and activators of transcription in the outcome of IFN
therapy for chronic hepatitis C. Intervirology 2008, 51:394-399.
29. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L,
Filipowicz W, Heim MH: IFN signaling and treatment outcome in chronic
hepatitis C. Proc Natl Acad Sci USA 2008, 105:7034-9039.
doi:10.1186/1743-422X-7-265
Cite this article as: Poat et al.: Intracellular expression of IRF9 Stat fusion
protein overcomes the defective Jak-Stat signaling and inhibits HCV
RNA replication. Virology Journal 2010 7:265.
Poat et al. Virology Journal 2010, 7:265
http://www.virologyj.com/content/7/1/265
Page 12 of 12